Custo-efetividade do fator VII ativado recombinante (rFVIIa) e complexo protrombínico parcialmente ativado (CCPa) no tratamento sob demanda do sangramento leve/moderado de pacientes com hemofilia congênita complicada por inibidores sob a perspectiva do sistema público de saúde do Brasil

Pepe, Camila; Fagundes, Gabriel Zaiden Zara; Goode, Brandon; Gonçalves, Thiago de Menezes; Tobaruella, Flávia Sauer.
J. bras. econ. saúde (Impr.) ; 9(3): 249-259, Dez. 2017.
Artigo em Português | LILACS, ECOS | ID: biblio-883004

Documentos relacionados

  1. aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model.
  2. Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea.
  3. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada.
  4. Engineering the Cyclization Loop of MCoTI-II Generates Targeted Cyclotides that Potently Inhibit Factor XIIa.
  5. An economic analysis of different treatments for bleeding in patients with acquired haemophilia.
  6. Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain.
  7. Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru.
  8. Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France.
  9. Personalized Prophylaxis with myPKFiT<sup>CE</sup>: A Real-World Cost-Effectiveness Analysis in Haemophilia A Patients.
  10. Cost-effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India.